Explore / Peer-reviewed article
Peer-reviewed article

Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.

Ghaznavi SiD, Richter SGiD

DrugsMar 24, 2025United States4 citationsDOI: 10.1007/s40265-025-02172-2

Abstract

There has been a recent resurgence in research on psychedelics as therapeutic agents for psychiatric conditions. This leading article outlines the studies to date of classic psychedelic treatments for treatment-resistant depression and major depression, including psilocybin, ayahuasca, dimethyltryptamine (DMT), and O-methyl-bufotenine (5-Me-O DMT). We discuss the potential of expanding treatment options for depression based on the data available, as well as the difficulties and limitations of research on psychedelics that make assessing that potential more challenging.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinAyahuascaDMT5-MeO-DMTDepression

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.